SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Macsween KF, Crawford DH. Epstein-Barr virus—recent advances. Lancet Infect Dis 2003;3:131140.
  • 2
    Okano M. Haematological associations of Epstein-Barr virus infection. Bailliere's Clin Haematol 2000;13:199214.
  • 3
    Horwitz CA, Henle W, Henle G, Schmitz H. Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med 1975;58:330338.
  • 4
    Tobi M, Ravid Z, Feldman-Weiss V, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1982;i:6163.
  • 5
    Dubois RE, Seely JK, Brus I, et al. Chronic mononucleosis syndrome. South Med J 1984;77:13761382.
  • 6
    Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence of active Epstein-Barr virus infection in patients with unexplained illness: elevated anti-early antigen antibodies. Ann Intern Med 1985;102:16.
  • 7
    Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985;102:716.
  • 8
    Rickinson AB. Chronic, symptomatic Epstein-Barr virus infections. Immunol Today 1986;7:1314.
  • 9
    Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet 1978;ii:231234.
  • 10
    Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988;157:405412.
  • 11
    Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991;4:129135.
  • 12
    Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infection. N Engl J Med 1988;318:733741.
  • 13
    Kanegane H, Bhatia K, Gutierrez M, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T cell lymphoma. Blood 1998;91:20852091.
  • 14
    Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996;87:14461457.
  • 15
    Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol/Hematol 2002;44:273282.
  • 16
    Kawa K, Okamura T, Yasui M, Sato E, Inoue M. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol/Hematol 2002;44:251257.
  • 17
    Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol 2003;40:124132.
  • 18
    Suzuki K, Oshima K, Karube K, et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol 2004;24:11651174.
  • 19
    Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280286.
  • 20
    Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003;187:527533.
  • 21
    Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr 1995;84:12711275.
  • 22
    Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993;92:14441450.
  • 23
    Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 1999;93:18691874.
  • 24
    Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD-3 negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989;84:5155.
  • 25
    Ishihara S, Tawa A, Yumura-Yagi K, et al. Clonal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection. Jpn J Cancer Res 1989;80:94100.
  • 26
    Ishihara S, Ohshima K, Tokura Y, et al. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. Jpn J Cancer Res 1997;88:8287.
  • 27
    Tokura Y, Ishihara S, Ohshima K, et al. Severe mosquito bite hypersensitivity, natural killer cell leukemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. Br J Dermatol 1998;138:905906.
  • 28
    Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999;37:132136.
  • 29
    Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis 1999;179:10121015.
  • 30
    Patel S, Zuckerman M, Smith M. Real-time quantitative PCR of Epstein-Barr virus BZLF1 DNA using the LightCycler. J Virol Methods 2003;109:227233.
  • 31
    Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001;98:18821888.
  • 32
    Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol 1999;73:965975.
  • 33
    Kikuta H, Nakanishi M, Sakiyama Y, Matsumoto S. Chronic active Epstein-Barr virus (EBV) infection is associated with clonotypic intracellular terminal regions of the EBV. J Infect Dis 1989;160:546547.
  • 34
    Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol 2001;82:23852392.
  • 35
    Taketani T, Kikuchi A, Inatomi J, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;29:531533.
  • 36
    Oshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 1998;48:934943.
  • 37
    Oshima K, Suzumiya J, Ohga S, Ohgami A, Kikuchi M. Integrated Epstein-Barr virus (EBV) and chromosomal abnormality in chronic active EBV infection. Int J Cancer 1997;71:943947.
  • 38
    Zhang Y, Nagata H, Ikeuchi T, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003;121:805814.
  • 39
    Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its mutation. Blood 2004;103:12441252.
  • 40
    Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000;96:31183125.
  • 41
    Mitarnun W, Suwiwat S, Pradutkanchana J, et al. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative diseases/lymphoma: clinicopathologic, serologic, and molecular analysis. Am J Hematol 2002;70:3138.
  • 42
    Au W-Y, Pang A, Choy C, Chim CS, Kwong Y-L. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243249.
  • 43
    Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology 2001:259281.
  • 44
    Ichima K, Kagami Y, Suzuki R, et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites. Pathol Int 2003;53:333344.
  • 45
    Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis 1997;176:254257.
  • 46
    Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001;183:17.
  • 47
    Tabiasco J, Vercellone A, Meggetto F, Hudrisier D, Brousset P, Fournie J-J. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 2003;170:59935998.
  • 48
    Isobe Y, Sugimoto K, Yang L, et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004;64:21672174.
  • 49
    Okano M. Therapeutic approaches for severe Epstein-Barr virus infection. Pediatr Hematol Oncol 1997;14:109119.
  • 50
    Savoldo B, Hhuls AH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100:40594066.
  • 51
    Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus lymphoproliferation. Lancet 2000;356:223224.